Literature DB >> 26540357

Lower Risk of Intracranial Arteriovenous Malformation Hemorrhage in Patients With Hereditary Hemorrhagic Telangiectasia.

Wuyang Yang1, Ann Liu, Alice L Hung, Maria Braileanu, Joanna Y Wang, Justin M Caplan, Geoffrey P Colby, Alexander L Coon, Rafael J Tamargo, Edward S Ahn, Judy Huang.   

Abstract

BACKGROUND: Patients diagnosed with hereditary hemorrhagic telangiectasia (HHT) are at risk of developing intracranial arteriovenous malformations (AVM). However, the clinical manifestations and natural history of HHT-related AVMs remain unclear due to the rarity of these lesions.
OBJECTIVE: To clarify the clinical characteristics and hemorrhagic risk in HHT-related AVMs.
METHODS: We performed a retrospective review of all patients diagnosed with both HHT and intracranial AVMs who were evaluated at our institution from 1990 to 2013. Patients with missing data or lost to follow-up were excluded. Baseline characteristics and subsequent hemorrhagic risk were evaluated.
RESULTS: In an AVM database of 531 patients with 542 AVMs, a total of 12 HHT patients (2.3%) with 23 AVMs were found. Mean age at diagnosis was 36.5 years, with 41.7% male. Compared to patients with sporadic AVMs, patients with HHT were less likely to present with ruptured AVM (P = .04), headaches (P = .02), and seizures (P = .02), and presented with better modified Rankin scores (P < .01). HHT-related AVMs were smaller in size (P < .01), of lower Spetzler-Martin grade (P = .01), and had less temporal lobe involvement (P = .02) compared to sporadic AVMs. Six HHT patients (50.0%) were found with multiple intracranial AVMs. One hemorrhage was found during an observation period of 149.6 patient-years and 297.5 lesion-years, translating to 1.3% per patient per year or 0.7% per AVM per year.
CONCLUSION: HHT-related AVMs are smaller in size with lower Spetzler-Martin grade and less temporal lobe involvement than sporadic AVMs. Patients with HHT frequently present with multiple intracranial AVMs. Conservative management is generally recommended due to lesion multiplicity and relatively low hemorrhagic risk.

Entities:  

Mesh:

Year:  2016        PMID: 26540357     DOI: 10.1227/NEU.0000000000001103

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

Review 1.  Angioarchitecture of Hereditary Arteriovenous Malformations.

Authors:  Patricia E Burrows
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

2.  Comparison of MRI, MRA, and DSA for Detection of Cerebral Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.

Authors:  M Vella; M D Alexander; M C Mabray; D L Cooke; M R Amans; C M Glastonbury; H Kim; M W Wilson; D E Langston; M B Conrad; S W Hetts
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

3.  Surgical Treatment vs Nonsurgical Treatment for Brain Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia: A Retrospective Multicenter Consortium Study.

Authors:  Ali Tayebi Meybodi; Helen Kim; Jeffrey Nelson; Steven W Hetts; Timo Krings; Karel G terBrugge; Marie E Faughnan; Michael T Lawton
Journal:  Neurosurgery       Date:  2018-01-01       Impact factor: 4.654

Review 4.  Systemic and CNS manifestations of inherited cerebrovascular malformations.

Authors:  Blaine L Hart; Marc C Mabray; Leslie Morrison; Kevin J Whitehead; Helen Kim
Journal:  Clin Imaging       Date:  2021-01-20       Impact factor: 2.420

5.  European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT).

Authors:  Omer F Eker; Edoardo Boccardi; Ulrich Sure; Maneesh C Patel; Saverio Alicante; Ali Alsafi; Nicola Coote; Freya Droege; Olivier Dupuis; Annette Dam Fialla; Bryony Jones; Ujwal Kariholu; Anette D Kjeldsen; David Lefroy; Gennaro M Lenato; Hans Jurgen Mager; Guido Manfredi; Troels H Nielsen; Fabio Pagella; Marco C Post; Catherine Rennie; Carlo Sabbà; Patrizia Suppressa; Pernille M Toerring; Sara Ugolini; Elisabetta Buscarini; Sophie Dupuis-Girod; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2020-06-29       Impact factor: 4.123

6.  Benefits of Treating Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia: A Retrospective Analysis of 14 Patients.

Authors:  M Neil Woodall; Peter Nakaji; Robert F Spetzler
Journal:  World Neurosurg X       Date:  2019-03-09

7.  Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia.

Authors:  K P Thompson; J Nelson; H Kim; S M Weinsheimer; D A Marchuk; M T Lawton; T Krings; M E Faughnan
Journal:  Orphanet J Rare Dis       Date:  2021-09-19       Impact factor: 4.123

8.  NAPG mutation in family members with hereditary hemorrhagic telangiectasia in China.

Authors:  Yu Xu; Yong-Biao Zhang; Li-Jun Liang; Jia-Li Tian; Jin-Ming Lin; Pan-Pan Wang; Rong-Hui Li; Ming-Liang Gu; Zhan-Cheng Gao
Journal:  BMC Pulm Med       Date:  2021-06-10       Impact factor: 3.317

9.  Intermixed arteriovenous malformation and hemangioblastoma: case report and literature review.

Authors:  Vincent Healy; Philip J O'Halloran; Mohammed B Husien; Ciaran Bolger; Michael Farrell
Journal:  CNS Oncol       Date:  2020-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.